… This study aimed to examine the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for
coronavirus disease 2019 (COVID-19). PubMed, Cochrane Library, Web of Science, medRxiv, …

… our metaanalysis showed that nirmatrelvir–ritonavir reduced … rate was lower in the
nirmatrelvir–ritonavir group (RR 0.55; 95… significantly between the nirmatrelvir–ritonavir and the …

… This study aimed to compare the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid)
with … Data were analyzed using Comprehensive Meta-Analysis software. Eighteen studies …

… research results of nirmatrelvir–ritonavir compared with other … and safety of nirmatrelvir–ritonavir
compared with other … meta-analysis to estimate the effects of nirmatrelvir–ritonavir …

… studies and those with incomplete data were excluded from our meta-analysis. Original
studies that used only nirmatrelvir rather than nirmatrelvir–ritonavir combo were excluded. …

… review and meta-analysis was to evaluate the effectiveness of nirmatrelvir-ritonavir treatment
… This study found that nirmatrelvir-ritonavir treatment was associated with a reduced risk of …

… indicates that there is no significant difference between nirmatrelvir/ritonavir and sotrovimab
… The present meta-analysis revealed that treatment with nirmatrelvir/ritonavir did not show …

… Methods: Observational studies of nirmatrelvir/ritonavir or molnupiravir compared to no …
with nirmatrelvir/ritonavir (n = 462 279) and molnupiravir (n = 48 008). Nirmatrelvir/ritonavir …

Nirmatrelvir‐ritonavir (NR) was approved to treat SARS‐CoV‐2 positive outpatients at high
risk of progression to severe disease, based on a randomized trial in unvaccinated patients. …

… mild to moderate patients: nirmatrelvir plus ritonavir (NMV-r) [1] … Nirmatrelvir is the main
protease inhibitor (Mpro) of severe … increased by the administration of ritonavir, a CYP3A inhibitor […